PE20130810A1 - Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina - Google Patents

Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina

Info

Publication number
PE20130810A1
PE20130810A1 PE2013000265A PE2013000265A PE20130810A1 PE 20130810 A1 PE20130810 A1 PE 20130810A1 PE 2013000265 A PE2013000265 A PE 2013000265A PE 2013000265 A PE2013000265 A PE 2013000265A PE 20130810 A1 PE20130810 A1 PE 20130810A1
Authority
PE
Peru
Prior art keywords
compounds
bradiquinin
tetrahydrofuranil
disustituted
antagonists
Prior art date
Application number
PE2013000265A
Other languages
English (en)
Inventor
Norbert Hauel
Raimund Kuelzer
Angelo Ceci
Henri Doods
Birgit Jung
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20130810A1 publication Critical patent/PE20130810A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

SE REFIERE A COMPUESTOS DE TETRAHIDROFURANILO DISUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR B1 DE BRADIQUININA DE FORMULA I, DONDE R1 ES UN GRUPO: 3-AMINO-PIRIDINA-5-IL; 5-PIRIMIDINIL ENTRE OTROS; R2 ES H, CL, F; X ES CH, N, ENANTIOMEROS, DIASTEREOISOMEROS, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: {3-[2-FLUORO-4-(4-METOXI-2-TRIFLUOROMETIL-FENILAMINO)-BENCILCARBAMOIL]-TETRAHIDROFURAN-3-IL}-AMIDA DEL ACIDA(S)-6-OXO-1,6-DIHIDRO-PIRIDAZIN-4-CARBOXILICO; (S)-5-AMINO-N-{3-[2-FLUORO-4-(4-METOXI-2-TRIFLUORMETIL-FENILAMINO)-BENCILCARBAMOIL]-TETRAHIDROFURAN-3-IL}-NICOTINAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO FARMACEUTICO. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO AGUDO Y PROFILACTICO DE DOLORES VISCERALES, NEUROPATICOS ENTRE OTROS.
PE2013000265A 2010-08-20 2011-08-19 Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina PE20130810A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10173489 2010-08-20

Publications (1)

Publication Number Publication Date
PE20130810A1 true PE20130810A1 (es) 2013-07-25

Family

ID=44510978

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000265A PE20130810A1 (es) 2010-08-20 2011-08-19 Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina

Country Status (36)

Country Link
US (1) US8937073B2 (es)
EP (1) EP2606042B1 (es)
JP (1) JP5727011B2 (es)
KR (1) KR101822371B1 (es)
CN (1) CN103068817B (es)
AP (1) AP2012006630A0 (es)
AR (1) AR082507A1 (es)
AU (1) AU2011290727B2 (es)
BR (1) BR112013003752A2 (es)
CA (1) CA2807086A1 (es)
CL (1) CL2013000310A1 (es)
CO (1) CO6680689A2 (es)
CY (1) CY1115933T1 (es)
DK (1) DK2606042T3 (es)
EA (1) EA022787B1 (es)
EC (1) ECSP13012495A (es)
ES (1) ES2525296T3 (es)
GE (1) GEP20146196B (es)
HK (1) HK1178902A1 (es)
HR (1) HRP20141172T1 (es)
IL (1) IL224039A (es)
MA (1) MA34578B1 (es)
ME (1) ME01899B (es)
MX (1) MX352548B (es)
MY (1) MY156233A (es)
NZ (1) NZ607435A (es)
PE (1) PE20130810A1 (es)
PL (1) PL2606042T3 (es)
PT (1) PT2606042E (es)
RS (1) RS53622B1 (es)
SG (1) SG187835A1 (es)
SI (1) SI2606042T1 (es)
TW (1) TWI548632B (es)
UA (1) UA108765C2 (es)
UY (1) UY33565A (es)
WO (1) WO2012022795A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007034620A1 (de) * 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
EP2188254B1 (de) 2007-08-29 2012-03-21 Boehringer Ingelheim International GmbH Neue bradykinin b1-antagonisten
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
US11401303B2 (en) * 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259079B (en) 2002-02-08 2006-08-01 Merck & Co Inc N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives
ATE316954T1 (de) * 2002-02-08 2006-02-15 Merck & Co Inc N-biphenylmethylaminocycloalkancarboxamid- derivative
US7163951B2 (en) 2002-08-29 2007-01-16 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
CA2534188A1 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides
CN1832922A (zh) * 2003-08-07 2006-09-13 默克公司 磺酰基取代的n－(联芳基甲基)氨基环丙烷甲酰胺类
JP2007526311A (ja) * 2004-03-02 2007-09-13 メルク　エンド　カムパニー　インコーポレーテッド ブラジキニンアンタゴニストとしてのアミノシクロプロパンカルボキサミド誘導体
US20060173023A1 (en) 2005-02-01 2006-08-03 Wood Michael R 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation
WO2008033564A1 (en) * 2006-09-15 2008-03-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
HUP0600809A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
DE102007034620A1 (de) 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
EP2025675A1 (de) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
EP2188254B1 (de) 2007-08-29 2012-03-21 Boehringer Ingelheim International GmbH Neue bradykinin b1-antagonisten
AR068509A1 (es) 2007-09-19 2009-11-18 Jerini Ag Antagosnistas del receptor de bradiquinina b1
WO2010057899A1 (de) 2008-11-20 2010-05-27 Boehringer Ingelheim International Gmbh Cykloalkylaminocarbonylderivate als bradykinin-b1-rezeptor antagonisten
WO2010097374A1 (de) 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Verbindungen als bradykinin-b1-antagonisten
BRPI1008779A2 (pt) 2009-02-26 2020-12-22 Boehringer Ingelheim International Gmbh. Compostos como antagonistas de bradiquinina-b1
KR101843341B1 (ko) 2010-02-23 2018-03-30 베링거 인겔하임 인터내셔날 게엠베하 브라디키닌 ｂ１ 길항제로서의 화합물
JP5934212B2 (ja) 2010-08-20 2016-06-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 複数のプロスタグランジン受容体に作用し、一般的な抗炎症反応を生じる化合物
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
US8901127B2 (en) 2010-08-20 2014-12-02 Boehringer Ingelheim International Gmbh Pyridazin derivatives as antagonists of the bradykinin B1 receptor
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1

Also Published As

Publication number Publication date
AR082507A1 (es) 2012-12-12
UY33565A (es) 2012-03-30
RS53622B1 (en) 2015-04-30
EA022787B1 (ru) 2016-03-31
EP2606042B1 (de) 2014-09-03
KR101822371B1 (ko) 2018-01-31
PL2606042T3 (pl) 2015-03-31
MX2013001965A (es) 2013-05-09
NZ607435A (en) 2015-07-31
AU2011290727A1 (en) 2013-03-14
HK1178902A1 (en) 2013-09-19
WO2012022795A1 (de) 2012-02-23
MY156233A (en) 2016-01-29
IL224039A (en) 2016-03-31
CN103068817B (zh) 2014-10-29
EA201201662A1 (ru) 2013-07-30
ES2525296T3 (es) 2014-12-19
SI2606042T1 (sl) 2014-12-31
ME01899B (me) 2014-12-20
PT2606042E (pt) 2014-10-15
HRP20141172T1 (hr) 2015-02-13
TWI548632B (zh) 2016-09-11
KR20130114082A (ko) 2013-10-16
DK2606042T3 (da) 2014-12-08
US20120208823A1 (en) 2012-08-16
BR112013003752A2 (pt) 2016-05-31
ECSP13012495A (es) 2013-04-30
CO6680689A2 (es) 2013-05-31
CA2807086A1 (en) 2012-02-23
JP2013534238A (ja) 2013-09-02
GEP20146196B (en) 2014-11-10
UA108765C2 (xx) 2015-06-10
AP2012006630A0 (en) 2012-12-31
CL2013000310A1 (es) 2013-04-01
AU2011290727B2 (en) 2015-07-16
EP2606042A1 (de) 2013-06-26
CY1115933T1 (el) 2017-01-25
US8937073B2 (en) 2015-01-20
MA34578B1 (fr) 2013-10-02
TW201305145A (zh) 2013-02-01
CN103068817A (zh) 2013-04-24
JP5727011B2 (ja) 2015-06-03
MX352548B (es) 2017-11-29
SG187835A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
PE20130810A1 (es) Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina
NZ590650A (en) Buprenorphine analogs
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
EA201590748A1 (ru) Противовирусные соединения против rsv
PE20121180A1 (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
GEP201706728B (en) Noxious organism control agent
EA201490579A1 (ru) Новые хиральные n-ацил-5,6,7,(8-замещенные)тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
ECSP11011151A (es) Compuestos purina
IL199972A (en) Tricyclic compounds and their use as modulators of glucocorticoid receptor
PE20142359A1 (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
EA201290073A1 (ru) Соединения мочевины, содержащие 5,6-бициклический гетероарил, как ингибиторы киназ
PE20121438A1 (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
PE20151748A1 (es) Inhibidores de bace1
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
PH12015500398B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
MX360330B (es) Regimen de administracion para nitrocatecoles.
PE20140998A1 (es) Compuestos heterociclicos como inhibidores de syk
MX2014010910A (es) Sales novedosas de trimebutina basadas en sulfonato.
EA200901391A1 (ru) Пиримидинилпиперазины, применимые в качестве лигандов рецепторов d/d
MX2009008286A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed